Skip to content

Study · Observational study · n = 184 · 2025

4 results

Safety and efficacy of weekly somapacitan for growth hormone deficiency in children: A 72-week observational study.

Al-Agha AE, Aljefri HM, Kafi SE, Alamri AS, Alghamdi AA

Saudi medical journal1 Mar 2025Cited by 2 (Europe PMC)

PMID40096976 (opens in a new tab)PMCIDPMC11918665 (opens in a new tab)DOI10.15537/smj.2025.46.3.20240937 (opens in a new tab)PepBankPUB-40096976
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In children with GHD receiving somapacitan, IGF-1 levels increased from 166.97 to 363.74 by week 72.

    In plain wordsIn children with GHD, somapacitan treatment was linked to higher IGF-1 levels than baseline.

    Peptide
    Somapacitan
    Outcome
    IncreaseIGF-1 levels
    Study

    n = 184

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Starting at 0.16 mg/kg weekly, adjusted to IGF-1As given in this study (human).

    Measurements

    IGF-1
    166.97
    baseline
    IGF-1
    363.74
    week 72

    Source sentences

    Summary
    The cohort, with an average age of 10.1 years and 67.4% male, showed substantial improvements by week 72: IGF-1 levels increased from 166.97 to 363.74, and height velocity gains were most pronounced in children at Tanner Stage 1.
    3 context sentences
    Summary · context
    The observational study included 184 children diagnosed with GHD.
    Summary · context
    Carried out over 72 weeks at the Pediatric Endocrinology Outpatient Clinic in collaboration with King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
    Summary · context
    Patients received weekly somapacitan doses, starting at 0.16 mg/kg and adjusted according to insulin-like growth factor 1 (IGF-1) levels.
  2. 02HumanObservational studySafety outcome

    In children with GHD, somapacitan was well tolerated with minimal side effects.

    In plain wordsIn children with GHD, somapacitan was well tolerated with minimal side effects.

    Peptide
    Somapacitan
    Outcome
    Not applicableTolerability
    Study

    n = 184

    Outcome group
    Adverse events · Whole body
    Studied dose
    Starting at 0.16 mg/kg weekly, adjusted to IGF-1As given in this study (human).

    Source sentences

    Summary
    Somapacitan was well-tolerated, with minimal side effects, supporting its long-term safety.
    3 context sentences
    Summary · context
    The observational study included 184 children diagnosed with GHD.
    Summary · context
    Carried out over 72 weeks at the Pediatric Endocrinology Outpatient Clinic in collaboration with King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
    Summary · context
    Patients received weekly somapacitan doses, starting at 0.16 mg/kg and adjusted according to insulin-like growth factor 1 (IGF-1) levels.
  3. 03HumanObservational studyEfficacy outcome

    In children receiving somapacitan for GHD, height velocity gains were most pronounced at Tanner Stage 1.

    In plain wordsIn children receiving somapacitan for GHD, Tanner Stage 1 was linked to greater height velocity gains than other stages.

    Peptide
    Somapacitan
    Outcome
    IncreaseHeight velocity by Tanner stage
    Study

    n: not reported in source

    Comparator
    Other Tanner stages
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Starting at 0.16 mg/kg weekly, adjusted to IGF-1As given in this study (human).

    Source sentences

    Summary
    The cohort, with an average age of 10.1 years and 67.4% male, showed substantial improvements by week 72: IGF-1 levels increased from 166.97 to 363.74, and height velocity gains were most pronounced in children at Tanner Stage 1.
    3 context sentences
    Summary · context
    The observational study included 184 children diagnosed with GHD.
    Summary · context
    Carried out over 72 weeks at the Pediatric Endocrinology Outpatient Clinic in collaboration with King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
    Summary · context
    Patients received weekly somapacitan doses, starting at 0.16 mg/kg and adjusted according to insulin-like growth factor 1 (IGF-1) levels.
  4. 04HumanObservational studyEfficacy outcome

    In children receiving somapacitan for GHD, treatment-naive children had greater initial height velocity improvements than switchers, but differences later leveled.

    In plain wordsIn children receiving somapacitan, no previous GH treatment was linked to greater initial height velocity gains than switching, but differences later leveled.

    Peptide
    Somapacitan
    Outcome
    MixedHeight velocity by previous treatment
    Study

    n: not reported in source

    Comparator
    Children switching from daily GH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Starting at 0.16 mg/kg weekly, adjusted to IGF-1As given in this study (human).

    Source sentences

    Summary
    Treatment-naive children exhibited greater initial height velocity improvements compared to those switching from daily GH therapy, although these differences leveled over time.
    3 context sentences
    Summary · context
    The observational study included 184 children diagnosed with GHD.
    Summary · context
    Carried out over 72 weeks at the Pediatric Endocrinology Outpatient Clinic in collaboration with King Abdulaziz University Hospital in Jeddah, Saudi Arabia.
    Summary · context
    Patients received weekly somapacitan doses, starting at 0.16 mg/kg and adjusted according to insulin-like growth factor 1 (IGF-1) levels.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.